Konitsiotis Spiros, Pappa Sofia, Mantas Christos, Mavreas Venos
Department of Neurology, University of Ioannina Medical School, Ioannina, Greece.
Mov Disord. 2006 Aug;21(8):1219-21. doi: 10.1002/mds.20835.
Levetiracetam (LEV), a novel antiepileptic drug, has demonstrated antidyskinetic effect in preclinical animal models of Parkinson's disease (PD) and in one open label study in PD patients with levodopa-induced dyskinesia. The acute antidyskinetic effects of LEV in patients with tardive dyskinesia were evaluated in an open label study. Eight patients received oral LEV (1,000 mg/day) for 1 month and blinded evaluations were performed at baseline and at the end of the treatment period. A significant reduction of the abnormal movements was recorded while psychiatric symptoms did not worsen and the adverse event profile was benign. LEV may be efficacious for the treatment of tardive dyskinesia and deserves further clinical testing.
左乙拉西坦（LEV）是一种新型抗癫痫药物，已在帕金森病（PD）的临床前动物模型以及一项针对左旋多巴诱导的异动症的PD患者的开放标签研究中显示出抗异动症作用。在一项开放标签研究中评估了左乙拉西坦对迟发性运动障碍患者的急性抗异动症作用。8例患者口服左乙拉西坦（1000mg/天），疗程1个月，并在基线期和治疗期末进行盲法评估。记录到异常运动明显减少，而精神症状未恶化，不良事件情况良好。左乙拉西坦可能对迟发性运动障碍有效，值得进一步进行临床试验。
